Skip to content
Login Register

#hybridoma

12 public questions tagged with this topic.

Immunological Applications

HAT medium contains:

HAT selective medium developed by John Littlefield in 1964 exploits metabolic auxotrophy to isolate somatic hybrids based on nucleotide salvage capability. Base medium DMEM or RPMI supplemented with fetal bovine serum provides carbon source, but three selective additives define HAT: hypoxanthine at 100 micromolar serving as purine base for salvage via hypoxanthine-guanine phosphoribosyltransferase converting to inosine monophosphate using phosphoribosyl pyrophosphate donor, thymidine at 16 micromolar supplying pyrimidine salvage substrate for thymidine kinase isoforms TK1 cytosolic and TK2 mit

Ref: Littlefield Science 1964 145:709 HAT selection; Szybalski Biochem Pharmacol HAT hypoxanthine aminopterin thymidine composition.

View Details
Immunological Applications

PEG (polyethylene glycol) is used in hybridoma technology for:

Efficient cell fusion must overcome hydration repulsion keeping lipid bilayers approximately two nanometers apart due to ordered water molecules bound to phosphatidylcholine headgroups. Polyethylene glycol with molecular weight 1450 to 4000 daltons is extremely hygroscopic linear polymer containing repeating ether oxygens that strongly bind water through hydrogen bonding, lowering water activity dramatically and creating osmotic stress that forces membranes into close proximity below one nanometer. At concentrated 40 to 50 percent weight per volume, PEG disrupts lipid packing, induces inverted

Ref: Lentz J Mol Biol PEG fusion membrane dehydration; Alberts MBoC membrane fusion hemifusion stalk; Nature Protocols PEG hybridoma.

View Details
Immunological Applications

The main purpose of using myeloma cells in hybridoma technology is:

Primary plasma cells cannot be cultured long term because they activate intrinsic mitochondrial apoptosis via Bim upregulation when removed from survival niche provided by stromal cell contact, interleukin-6, and BAFF, plus replicative senescence triggered by telomere shortening each division. Myeloma cells circumvent these barriers through multiple oncogenic lesions: expression of hTERT telomerase reverse transcriptase adding TTAGGG repeats preventing crisis, disruption of p53-MDM2 axis, loss of cyclin dependent kinase inhibitors p16 and p21, autocrine loops via IGF-1 and interleukin-6 consti

Ref: Freshney Culture Animal Cells 7th ed myeloma immortality hTERT; Abbas Cellular Molecular Immunology hybridoma immortalization.

View Details
Immunological Applications

Hybridoma technology involves fusion of:

Hybridoma formation relies on merging two complementary cellular programs within one cytoplasm to create self-renewing antibody factory. Splenic B lymphocytes from immunized donor possess productively rearranged heavy chain locus on chromosome 14 with VDJ recombination mediated by RAG1/2 and light chain kappa or lambda locus with VJ recombination, encoding high-affinity combining site selected through germinal center affinity maturation involving activation-induced deaminase, but they senesce within days after extraction due to lack of telomerase, dependence on BAFF survival signal, and activa

Ref: Janeway Immunobiology 9th ed monoclonal generation; J Genet Eng Biotechnol 2020 PMC7414427 hybridoma fusion B myeloma.

View Details
Immunological Applications

Monoclonal antibodies are produced by:

Mammalian antibody-secreting plasma cells are terminally differentiated, possessing an extensively expanded endoplasmic reticulum and unfolded protein response activated to sustain immunoglobulin production at up to 10,000 molecules per second, but these cells quickly trigger p53 dependent apoptosis and survive only days in vitro. To overcome limited lifespan, Georges Kohler and Cesar Milstein in 1975 created hybridoma technology that couples specificity donor with immortal partner. Splenic B lymphocytes isolated from hyperimmunized mouse provide functional heavy and light chain loci after som

Ref: Kohler & Milstein Nature 1975 256:495 hybridoma; Alberts Molecular Biology of Cell 6th ed Chapter 8 monoclonal production.

View Details
Immunological Applications

Monoclonal antibodies bind:

Bevacizumab recombinant humanized IgG1 mAb 149 kDa neutralizes soluble VEGF-A isoforms 121 165 189 206 secreted tumor stromal inflammatory cells hypoxia HIF1alpha binding hypoxia response elements driving transcription. VEGF-A binds VEGFR1 FLT1 and R2 KDR tyrosine kinases endothelial cells dimerization autophosphorylation Tyr1175 recruiting PLC gamma generating IP3 DAG increasing calcium PKC stimulating proliferation permeability via VE-cadherin internalization gaps survival Akt phosphorylation caspase-9. Binding epitope Arg82 Lys84 affinity 0.5 nM overlapping receptor binding interface preven

Ref: Ferrara NEJM Bevacizumab VEGF Targeted Therapy 2004; FDA Avastin Mechanism Label VEGF Neutralization; Lodish Angiogenesis VEGF Signaling Pathway Chapter 23.

View Details
Immunological Applications

Aminopterin in HAT medium functions by:

Antibody specificity arises exquisite three-dimensional complementarity between paratope heavy light chain variable domains epitope antigen surface determining binding free energy selectivity. Variable domains each contribute three complementarity-determining regions CDR1 CDR2 CDR3 loops supported conserved framework beta sheet Ig fold creating pocket groove protruding loop accommodating antigen features charged arginine aspartate hydrophobic tryptophan phenylalanine patches hydrogen bond donors carbohydrate. Binding stabilized hydrogen bonds CDR backbone carbonyl antigen side chain salt bridg

Ref: Janeway Antibody Specificity CDR Structure Affinity Chapter 5; NCBI Antibody Antigen Recognition Principles; Alberts Immunoglobulin Variable Region Specificity Chapter 24.

View Details
Immunological Applications

HAT medium contains:

HAT medium intelligent metabolic selection exploiting two distinct pathways nucleotide biosynthesis de novo synthesis requiring tetrahydrofolate one-carbon donor and salvage reusing preformed purines pyrimidines. Aminopterin potent folic acid analog competitively inhibits dihydrofolate reductase converting dihydrofolate tetrahydrofolate Ki 0.03 nM blocking regeneration tetrahydrofolate required thymidylate synthase converting dUMP dTMP purine enzymes GAR transformylase AICAR transformylase shutting de novo purine thymidine synthesis hours. Cell survival then depends entirely salvage enzymes HP

Ref: Littlefield Science 1964 HAT Selection Classic; Janeway Immunobiology HAT Composition Components Chapter 2; Lodish Cell Culture HAT Selection Principle Media.

View Details
Immunological Applications

PEG (polyethylene glycol) is used in hybridoma technology for:

Polyethylene glycol polymer repeating ethylene oxide units average MW 1500 Da widely employed fusogen hybridoma generation due unique physicochemical properties affecting membrane biophysics. Mechanism involves strong hygroscopic nature binding water around phospholipid headgroups phosphatidylcholine sphingomyelin reducing hydration repulsion normally maintaining 2-3 nm separation bilayers enabling close apposition

Ref: Kohler Milstein PEG Fusion Method 1976 Detailed; Alberts Membrane Fusion PEG Mechanism Biophysical; Janeway Hybridoma PEG Fusion Laboratory Protocol Chapter 5.

View Details
Immunological Applications

The main purpose of using myeloma cells in hybridoma technology is:

Primary B lymphocytes after differentiation short-lived plasma cells produce Ig extraordinary rate but survive 3-5 days culture due activation-induced death mediated Fas upregulation after strong BCR crosslinking and lack telomere maintenance somatic cells lacking telomerase entering senescence limited divisions dependence extrinsic survival signals CD40L helper T cells cytokines IL-4 IL-6 IL-21 follicular helper. Continuous monoclonal manufacturing over months requires immortalization essential. Myeloma plasmacytoma malignant transformation plasma cells proliferate indefinitely without exogen

Ref: Kohler Milstein Myeloma Immortality Principle 1975; Lodish Hybridoma Immortalization Mechanism Biology; Janeway Myeloma Fusion Purpose Immunobiology Chapter 2.

View Details
Immunological Applications

Hybridoma technology involves fusion of:

Somatic cell fusion underlying hybridoma merges two differentiated cell types each contributing specialized traits necessary monoclonal antibody manufacturing. Antigen-experienced B lymphocyte harvested spleen four days after final booster carries functionally rearranged Ig heavy VDJ and light VJ genes formed RAG1/RAG2 recombination junctional diversity somatic hypermutation conferring high affinity specificity target epitope active transcription intronic enhancer Emu 3 prime regulatory region capacity synthesizing Ig up to 2000 molecules per second but limited lifespan due lack telomerase dep

Ref: Janeway Hybridoma Fusion B cell Myeloma Mechanism 9th ed; Alberts Cell Fusion Mechanism Chapter 19; NCBI Kohler Milstein Hybridoma Methodology Original.

View Details
Immunological Applications

Monoclonal antibodies are produced by:

Monoclonal antibodies originate immortalized hybridoma lines fusing single antibody-secreting B lymphocyte with myeloma partner preserving exactly one immunoglobulin gene rearrangement producing uniform paratope. Protocol begins immunization BALB/c mice purified antigen HER2 extracellular domain mixed Freund's adjuvant stimulating germinal center spleen. Four days after final booster splenocytes enriched plasma blasts expressing high-affinity surface IgG harvested. Fusion mediated PEG 1500 or electrofusion aligning cells pearl chains creates heterokaryons containing nuclei both parents tetrapl

Ref: Kohler and Milstein Nature 1975 Hybridoma Monoclonal Generation; Janeway Hybridoma Technology Production Chapter 5; Lodish Antibody Production Hybridoma Cells Method.

View Details